Moreover, antibody against siglec-15, a sialic acid binding protein and T cell depressor, is expected to apply to cancer immunotherapy, offering another therapeutic tool for cancer patients resistant to current anti-PD-1/PD-L1 therapy [49]. This evidence concerns the gene CD274 and cancer.